相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PARP1 PARylates and stabilizes STAT5 in FLT3-ITD acute myeloid leukemia and other STAT5-activated cancers
Anna J. Dellomo et al.
TRANSLATIONAL ONCOLOGY (2022)
PARP goes the weasel! Emerging role of PARP inhibitors in acute leukemias
Claire Fritz et al.
BLOOD REVIEWS (2021)
TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition
Shiva Bamezai et al.
LEUKEMIA (2021)
MiR-181a enhances drug sensitivity of mixed lineage leukemia-rearranged acute myeloid leukemia by increasing poly(ADP-ribose) polymerase1 acetylation
Di Zhou et al.
LEUKEMIA & LYMPHOMA (2021)
Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML
Zuzana Tothova et al.
JCI INSIGHT (2021)
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
Susana Banerjee et al.
LANCET ONCOLOGY (2021)
Genotoxic therapy and resistance mechanism in gliomas
Fengchao Lang et al.
PHARMACOLOGY & THERAPEUTICS (2021)
Ovarian Cancer, Version 2.2020
Deborah K. Armstrong et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Prostate Cancer, Version 1.2021 Featured Updates to the NCCN Guidelines
Edward Schaeffer et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Histone Parylation factor 1 contributes to the inhibition of PARP1 by cancer drugs
Johannes Rudolph et al.
NATURE COMMUNICATIONS (2021)
The regulatory landscape of the human HPF1-and ARH3-dependent ADP-ribosylome
Ivo A. Hendriks et al.
NATURE COMMUNICATIONS (2021)
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database
Pierre-Marie Morice et al.
LANCET HAEMATOLOGY (2021)
Preexisting TP53-Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib
Tanya T. Kwan et al.
JAMA ONCOLOGY (2021)
Poly (ADP-ribose) polymerase inhibitors for arsenic trioxide-resistant acute promyelocytic leukemia: synergistic in vitro antitumor effects with hypomethylating agents or high-dose vitamin C
Manuela Giansanti et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2021)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
Andres Poveda et al.
LANCET ONCOLOGY (2021)
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Elizabeth M. Swisher et al.
NATURE COMMUNICATIONS (2021)
Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights
J. E. Martin et al.
ANNALS OF ONCOLOGY (2021)
TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors
Silvia Maifrede et al.
CANCER RESEARCH (2021)
Pamiparib: First Approval
Anthony Markham
DRUGS (2021)
PARP inhibitor maintenance for primary ovarian cancer - A missed opportunity for precision medicine
Stephanie L. Wethington et al.
GYNECOLOGIC ONCOLOGY (2021)
Serine-linked PARP1 auto-modification controls PARP inhibitor response
Evgeniia Prokhorova et al.
NATURE COMMUNICATIONS (2021)
Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
Antoine N. Saliba et al.
CANCER DRUG RESISTANCE (2021)
Breast Cancer, Version 4.2021 Featured Updates to the NCCN Guidelines
William J. Gradishar et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance
Rachel M. Hurley et al.
NAR CANCER (2021)
A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors
Jia Zhou et al.
NATURE CANCER (2021)
Targeting IDH1/2 mutant cancers with combinations of ATR and PARP inhibitors
Amrita Sule et al.
NAR CANCER (2021)
Pancreatic Adenocarcinoma, Version 2.2021
Margaret A. Tempero et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
Joaquin Mateo et al.
LANCET ONCOLOGY (2020)
The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index
Fabio Efficace et al.
LEUKEMIA (2020)
HPF1 completes the PARP active site for DNA damage-induced ADP-ribosylation
Marcin J. Suskiewicz et al.
NATURE (2020)
The impact of poly ADP ribose polymerase (PARP) inhibitors on clonal hematopoiesis.
Kelly L Bolton et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Olaparib for Metastatic Castration-Resistant Prostate Cancer
J. de Bono et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia
Alexandra Higgins et al.
GENES (2020)
Senescence and Cancer: A Review of Clinical Implications of Senescence and Senotherapies
Lynda Wyld et al.
CANCERS (2020)
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline
William P. Tew et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Synthetic lethal targeting ofTET2-mutant hematopoietic stem and progenitor cells (HSPCs) with TOP1-targeted drugs and PARP1 inhibitors
Chang-Bin Jing et al.
LEUKEMIA (2020)
Atypical Chronic Myeloid Leukemia: Where Are We Now?
Elena Crisa et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
Kelly L. Bolton et al.
NATURE GENETICS (2020)
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Maha Hussain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor
Yao Xiong et al.
NEOPLASIA (2020)
Discovery of Pamiparib (BGB-290), a Potent and Selective Poly (ADP-ribose) Polymerase (PARP) Inhibitor in Clinical Development
Hexiang Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia
Diletta Fontana et al.
HEMASPHERE (2020)
PARP1 inhibitor eliminated imatinib-refractory chronic myeloid leukemia cells in bone marrow microenvironment conditions
Paulina Podszywalow-Bartnicka et al.
LEUKEMIA & LYMPHOMA (2019)
Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders
Isabella Faraoni et al.
BIOCHEMICAL PHARMACOLOGY (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence
Hubert Fleury et al.
NATURE COMMUNICATIONS (2019)
Poly(ADP-ribose) polymerase-1 antagonizes DNA resection at double-strand breaks
Marie-Christine Caron et al.
NATURE COMMUNICATIONS (2019)
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
Deborah K. Armstrong et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)
Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes
Isabella Faraoni et al.
CANCERS (2019)
Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms
Pritesh R. Patel et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
I. Ray-Coquard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Kevin K. Lin et al.
CANCER DISCOVERY (2019)
Association of Chemotherapy for Solid Tumors With Development of Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in the Modern Era
Lindsay M. Morton et al.
JAMA ONCOLOGY (2019)
Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors
Silvia Maifrede et al.
BLOOD (2018)
The poly(ADP-ribose) polymerase inhibitor olaparib induces up-regulation of death receptors in primary acute myeloid leukemia blasts by NF-kappa B activation
Isabella Faraoni et al.
CANCER LETTERS (2018)
IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors
Remco J. Molenaar et al.
CLINICAL CANCER RESEARCH (2018)
PARP inhibitors and quality of life in ovarian cancer
Daisuke Aoki et al.
LANCET ONCOLOGY (2018)
Chromothripsis in acute myeloid leukemia: biological features and impact on survival
Maria Chiara Fontana et al.
LEUKEMIA (2018)
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
Stephen J. Pettitt et al.
NATURE COMMUNICATIONS (2018)
Mechanisms of PARP inhibitor sensitivity and resistance
Alan D. D'Andrea
DNA REPAIR (2018)
Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States
Rahul Shenolikar et al.
GYNECOLOGIC ONCOLOGY (2018)
Incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients (pts) with a germline (g) BRCA mutation (m) and platinum-sensitive relapsed ovarian cancer (PSR OC) receiving maintenance olaparib in SOLO2: Impact of prior lines of platinum therapy.
Jacob Korach et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
Olga Kondrashova et al.
NATURE COMMUNICATIONS (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma
Guy Pratt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia
Keith W. Pratz et al.
CLINICAL CANCER RESEARCH (2017)
A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia
Ivana Gojo et al.
CLINICAL CANCER RESEARCH (2017)
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors
Ann-Gerd Thorsell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells
Margaret Nieborowska-Skorska et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L. Coleman et al.
LANCET (2017)
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
Elizabeth M. Swisher et al.
LANCET ONCOLOGY (2017)
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Eric Pujade-Lauraine et al.
LANCET ONCOLOGY (2017)
A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia
Tamara B. Garcia et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Non-homologous DNA end joining and alternative pathways to double-strand break repair
Howard H. Y. Chang et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
R. C. Lindsley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity
Parker L. Sulkowski et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Ruxolitinib-induced defects in DNA repair cause sensitivity to PARP inhibitors in myeloproliferative neoplasms
Margaret Nieborowska-Skorska et al.
BLOOD (2017)
PARPi potentiates with current conventional therapy in MLL leukemia
Lu Zhao et al.
CELL CYCLE (2017)
MLL-AF9 leukemias are sensitive to PARP1 inhibitors combined with cytotoxic drugs
Silvia Maifrede et al.
BLOOD ADVANCES (2017)
Poly (ADP-ribose) polymerase inhibitors selectively induce cytotoxicity in TCF3-HLF-positive leukemic cells
Jinhua Piao et al.
CANCER LETTERS (2017)
Discovery and Characterization of (8S,9R)-5-Fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-2,7,8,9-tetrahydro-3H-pyrido[4,3,2-de]phthalazin-3-one (BMN 673, Talazoparib), a Novel, Highly Potent, and Orally Efficacious Poly(ADP-ribose) Polymerase-1/2 Inhibitor, as an Anticancer Agent
Bing Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
The leukemia-associated RUNX1/ETO oncoprotein confers a mutator phenotype
V. J. Forster et al.
LEUKEMIA (2016)
Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice
Jianhui Chang et al.
NATURE MEDICINE (2016)
Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors
Yi Zhu et al.
AGING CELL (2016)
Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer
Nidal E. Muvarak et al.
CANCER CELL (2016)
Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms
Keith W. Pratz et al.
CLINICAL CANCER RESEARCH (2016)
PARP-inhibitor-induced synthetic lethality for acute myeloid leukemia treatment
Lu Zhao et al.
EXPERIMENTAL HEMATOLOGY (2016)
Histone deacetylase inhibitors decrease NHEJ both by acetylation of repair factors and trapping of PARP1 at DNA double-strand breaks in chromatin
Carine Robert et al.
LEUKEMIA RESEARCH (2016)
Replication fork stability confers chemoresistance in BRCA-deficient cells
Arnab Ray Chaudhuri et al.
NATURE (2016)
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
M. R. Mirza et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Chemical genetic discovery of PARP targets reveals a role for PARP-1 in transcription elongation
Bryan A. Gibson et al.
SCIENCE (2016)
Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma
Elizabeth M. Swisher et al.
JAMA ONCOLOGY (2016)
The PARP Inhibitor Olaparib Antagonizes Leukemic Growth Induced By TET1 Overexpression in AML1-ETO Positive Acute Myeloid Leukemia
Shiva Bamezai et al.
BLOOD (2016)
BRCA1, PARP1 and γH2AAX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib
Isabella Faraoni et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2015)
Identification of novel PARP-1 inhibitors: Drug design, synthesis and biological evaluation
Zhouling Xie et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2015)
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
David P. Steensma et al.
BLOOD (2015)
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
Geoffrey Kim et al.
CLINICAL CANCER RESEARCH (2015)
Quantitative site-specific ADP-ribosylation profiling of DNA-dependent PARPs
Jean-Philippe Gagne et al.
DNA REPAIR (2015)
Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Clare L. Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Incidence, Presentation, and Prognosis of Malignancies in Ataxia-Telangiectasia: A Report From the French National Registry of Primary Immune Deficiencies
Felipe Suarez et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Niraparib: A Poly(ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination
Philip Jones et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
The Combination of the PARP Inhibitor Rucaparib and 5FU Is an Effective Strategy for Treating Acute Leukemias
Maria Vittoria Verga Falzacappa et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair
Raphael Ceccaldi et al.
NATURE (2015)
Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination
Pedro A. Mateos-Gomez et al.
NATURE (2015)
7Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors
Maria Teresa Esposito et al.
NATURE MEDICINE (2015)
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
J. Mateo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer
Linda Henneman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Inhibition of poly(ADP-ribose) polymerase 1 protects against acute myeloid leukemia by suppressing the myeloproliferative leukemia virus oncogene
Lingbo Wang et al.
ONCOTARGET (2015)
5mC-hydroxylase activity is influenced by the PARylation of TET1 enzyme
Fabio Ciccarone et al.
ONCOTARGET (2015)
High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome
Arjen H. G. Cleven et al.
MODERN PATHOLOGY (2015)
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
Terrence N. Wong et al.
NATURE (2015)
Downregulation of BRCA1 protein in BCR-ABL1 leukemia cells depends on stress-triggered TIAR-mediated suppression of translation
Paulina Podszywalow-Bartnicka et al.
CELL CYCLE (2014)
DNA damage accumulation and repair defects in acute myeloid leukemia: implications for pathogenesis, disease progression, and chemotherapy resistance
Maria Teresa Esposito et al.
CHROMOSOMA (2014)
PTIP associates with Artemis to dictate DNA repair pathway choice
Jiadong Wang et al.
GENES & DEVELOPMENT (2014)
Poly(ADP-ribose) Polymerase Inhibitors Sensitize Cancer Cells to Death Receptor-mediated Apoptosis by Enhancing Death Receptor Expression
X. Wei Meng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
PARP Inhibitors as P-glyoprotein Substrates
Denise Lawlor et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2014)
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Junko Murai et al.
MOLECULAR CANCER THERAPEUTICS (2014)
DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier
Margarida A. Santos et al.
NATURE (2014)
Requirement for Parp-1 and DNA ligases 1 or 3 but not of Xrcc1 in chromosomal translocation formation by backup end joining
Aashish Soni et al.
NUCLEIC ACIDS RESEARCH (2014)
The PARP inhibitor Olaparib disrupts base excision repair of 5-aza-2′-deoxycytidine lesions
Manuel Luis Orta et al.
NUCLEIC ACIDS RESEARCH (2014)
PARP1-Driven Poly-ADP-Ribosylation Regulates BRCA1 Function in Homologous Recombination-Mediated DNA Repair
Yiduo Hu et al.
CANCER DISCOVERY (2014)
Poly(ADP-ribosyl)ation is involved in the epigenetic control of TET1 gene transcription
Fabio Ciccarone et al.
ONCOTARGET (2014)
Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition
Junko Murai et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2014)
Function of BRCA1 in the DNA Damage Response Is Mediated by ADP-Ribosylation
Mo Li et al.
CANCER CELL (2013)
PARP-1 mechanism for coupling DNA damage detection to poly(ADP-ribose) synthesis
Marie-France Langelier et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2013)
Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia
Alan H. Shih et al.
HAEMATOLOGICA (2013)
Reprogramming cellular events by poly(ADP-ribose)-binding proteins
Jana Krietsch et al.
MOLECULAR ASPECTS OF MEDICINE (2013)
PARP-1 and gene regulation: Progress and puzzles
W. Lee Kraus et al.
MOLECULAR ASPECTS OF MEDICINE (2013)
Proteome-wide Identification of Poly(ADP-Ribosyl)ation Targets in Different Genotoxic Stress Responses
Stephanie Jungmichel et al.
MOLECULAR CELL (2013)
Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition
Matteo Berti et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2013)
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
Timothy J. Ley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Poly(ADP-ribose) binding to Chk1 at stalled replication forks is required for S-phase checkpoint activation
WooKee Min et al.
NATURE COMMUNICATIONS (2013)
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1-Mutated Mouse Mammary Tumors
Janneke E. Jaspers et al.
CANCER DISCOVERY (2013)
The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells
Silvana B. De Lorenzo et al.
FRONTIERS IN ONCOLOGY (2013)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
Mre11-Dependent Degradation of Stalled DNA Replication Forks Is Prevented by BRCA2 and PARP1
Songmin Ying et al.
CANCER RESEARCH (2012)
The Role of PARP-1 and PARP-2 Enzymes in Metabolic Regulation and Disease
Peter Bai et al.
CELL METABOLISM (2012)
Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias
Judith E. Karp et al.
CLINICAL CANCER RESEARCH (2012)
Recognition of the iso-ADP-ribose moiety in poly(ADP-ribose) by WWE domains suggests a general mechanism for poly (ADP-ribosyl)ation-dependent ubiquitination
Zhizhi Wang et al.
GENES & DEVELOPMENT (2012)
On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1
Xin Luo et al.
GENES & DEVELOPMENT (2012)
Enhanced Killing of Cancer Cells by Poly(ADP-ribose) Polymerase Inhibitors and Topoisomerase I Inhibitors Reflects Poisoning of Both Enzymes
Anand G. Patel et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors
Elisabet Wahlberg et al.
NATURE BIOTECHNOLOGY (2012)
New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
Bryan A. Gibson et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
Quantitative proteomics profiling of the poly(ADP-ribose)-related response to genotoxic stress
Jean-Philippe Gagne et al.
NUCLEIC ACIDS RESEARCH (2012)
Structural Basis for DNA Damage-Dependent Poly(ADP-ribosyl)ation by Human PARP-1
Marie-France Langelier et al.
SCIENCE (2012)
Mechanism of Generation of Therapy Related Leukemia in Response to Anti-Topoisomerase II Agents
Ian G. Cowell et al.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH (2012)
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML
Sabine Kayser et al.
BLOOD (2011)
Double-Strand Break Repair-Independent Role for BRCA2 in Blocking Stalled Replication Fork Degradation by MRE11
Katharina Schlacher et al.
CELL (2011)
Competition between PARP-1 and Ku70 control the decision between high-fidelity and mutagenic DNA repair
M. N. Paddock et al.
DNA REPAIR (2011)
Crystal Structures of Poly(ADP-ribose) Polymerase-1 (PARP-1) Zinc Fingers Bound to DNA STRUCTURAL AND FUNCTIONAL INSIGHTS INTO DNA-DEPENDENT PARP-1 ACTIVITY
Marie-France Langelier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
The USP1/UAF1 Complex Promotes Double-Strand Break Repair through Homologous Recombination
Junko Murai et al.
MOLECULAR AND CELLULAR BIOLOGY (2011)
PARP-3 and APLF Function Together to Accelerate Nonhomologous End-Joining
Stuart L. Rulten et al.
MOLECULAR CELL (2011)
Chromosomal Minimal Critical Regions in Therapy-Related Leukemia Appear Different from Those of De Novo Leukemia by High-Resolution aCGH
Nathalie Itzhar et al.
PLOS ONE (2011)
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
Anand G. Patel et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression
Christian Boehler et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Histone ADP-ribosylation in DNA repair, replication and transcription
Simon Messner et al.
TRENDS IN CELL BIOLOGY (2011)
Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy
Jinshui Fan et al.
BLOOD (2010)
Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination-Defective Cells
Ponnari Gottipati et al.
CANCER RESEARCH (2010)
53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
Samuel F. Bunting et al.
CELL (2010)
Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes
F. Al-Ejeh et al.
ONCOGENE (2010)
Toward a unified nomenclature for mammalian ADP-ribosyltransferases
Michael O. Hottiger et al.
TRENDS IN BIOCHEMICAL SCIENCES (2010)
PARP inhibition: PARP1 and beyond
Michele Rouleau et al.
NATURE REVIEWS CANCER (2010)
PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination
Helen E. Bryant et al.
EMBO JOURNAL (2009)
Inhibitors of poly ADP-ribose polymerase (PARP) induce apoptosis of myeloid leukemic cells: potential for therapy of myeloid leukemia and myelodysplastic syndromes
Terry J. Gaymes et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
The role of poly(ADP-ribosyl)ation in epigenetic events
Delphine Quenet et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Parp1 facilitates alternative NHEJ, whereas Parp2 suppresses IgH/c-myc translocations during immunoglobulin class switch recombination
Isabelle Robert et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and-2 Mutant Tumors
Philip Jones et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Identification of the ADP-Ribosylation Sites in the PARP-1 Automodification Domain: Analysis and Implications
Zhihua Tao et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2009)
Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways
Xuesong Liu et al.
MOLECULAR CANCER RESEARCH (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Molecular mechanism of poly(ADP-ribosyl)ation by PARP1 and identification of lysine residues as ADP-ribose acceptor sites
Matthias Altmeyer et al.
NUCLEIC ACIDS RESEARCH (2009)
JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders
Isabelle Plo et al.
BLOOD (2008)
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance
Elizabeth M. Swisher et al.
CANCER RESEARCH (2008)
Homologous recombination in DNA repair and DNA damage tolerance
Xuan Li et al.
CELL RESEARCH (2008)
A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity
Christopher J. Lord et al.
DNA REPAIR (2008)
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
Nicholas C. Turner et al.
EMBO JOURNAL (2008)
The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases
Paul O. Hassa et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2008)
Polyubiquitylation of PARP-1 Through Ubiquitin K48 Is Modulated by Activated DNA, NAD+, and Dipeptides
Tao Wang et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2008)
4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
Keith A. Menear et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
Substrate-Assisted Catalysis by PARP10 Limits Its Activity to Mono-ADP-Ribosylation
Henning Kleine et al.
MOLECULAR CELL (2008)
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Wataru Sakai et al.
NATURE (2008)
Resistance to therapy caused by intragenic deletion in BRCA2
Stacey L. Edwards et al.
NATURE (2008)
Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes
Jean-Philippe Gagne et al.
NUCLEIC ACIDS RESEARCH (2008)
P53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death
Ondrej Krejci et al.
BLOOD (2008)
PARP1-dependent kinetics of recruitment of MRE11 and NBS1 proteins to multiple DNA damage sites
Jean-Francois Haince et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
PARP inhibitor development for systemic cancer targeting
Tomasz Zaremba et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2007)
Ataxia telangiectasia mutated (ATM) signaling network is modulated by a novel poly(ADP-ribose)-dependent pathway in the early response to DNA-damaging agents
Jean-Francois Haince et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
ABT-888, an orallyactive poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models
Cherrie K. Donawho et al.
CLINICAL CANCER RESEARCH (2007)
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial
Huw D. Thomas et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Current development of clinical inhibitors of poly (ADP-ribose) polymerase in oncology
Kapila Ratnam et al.
CLINICAL CANCER RESEARCH (2007)
PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways
Minli Wang et al.
NUCLEIC ACIDS RESEARCH (2006)
DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412
C. H. Seedhouse et al.
LEUKEMIA (2006)
Identification of a molecular signature for leukemic promyelocytes and their normal counterparts: focus on DNA repair genes
I. Casorelli et al.
LEUKEMIA (2006)
Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: A mechanism for leukemia-specific HDI-dependent apoptosis?
Terry J. Gaymes et al.
MOLECULAR CANCER RESEARCH (2006)
Poly(ADP-ribose):: novel functions for an old molecule
Valerie Schreiber et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Parp-1 protects homologous recombination from interference by Ku and ligase IV in vertebrate cells
H Hochegger et al.
EMBO JOURNAL (2006)
DNA-induced dimerization of poly(ADP-ribose) polymerase-1 triggers its activation
E Pion et al.
BIOCHEMISTRY (2005)
In silico characterization of the family of PARP-like poly(ADP-ribosyl) transferases (pARTs) -: art. no. 139
H Otto et al.
BMC GENOMICS (2005)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and induces DNA strand break resealing
M Malanga et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Solution structure and DNA binding of the zinc-finger domain from DNA ligase IIIα
AW Kulczyk et al.
JOURNAL OF MOLECULAR BIOLOGY (2004)
Involvement of poly(ADP-ribose) polymerase-1 and XRCC1/DNA ligase III in an alternative route for DNA double-strand breaks rejoining
M Audebert et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks
YG Yang et al.
ONCOGENE (2004)
Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair
M Alcalay et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Poly(ADP-ribose) polymerase-1 dimerizes at a 5′ recessed DNA end in vitro:: A fluorescence study
E Pion et al.
BIOCHEMISTRY (2003)
Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination
N Schultz et al.
NUCLEIC ACIDS RESEARCH (2003)
Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks
A Celeste et al.
NATURE CELL BIOLOGY (2003)
Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1
V Schreiber et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The WWE domain: a common interaction module in protein ubiquitination and ADP ribosylation
L Aravind
TRENDS IN BIOCHEMICAL SCIENCES (2001)
分享论文
